The stock's rise snapped a four-day losing streak.
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
21h
Hosted on MSNAlltrna plans to tackle rare diseases using tRNA-based therapiesAlltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results